Evidence map›Paper›PMID 37905107›Full record

ArticlebioRxiv : the preprint server for biology2023

Trans-Lesion Synthesis and Mismatch Repair Pathway Crosstalk Defines Chemoresistance and Hypermutation Mechanisms in Glioblastoma.

Xing Cheng, Jing An, Jitong Lou, Qisheng Gu, Weimin Ding, Gaith Droby, Yilin Wang, Chenghao Wang, Yanzhe Gao, Abigail Shelton and 12 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Xing ChengDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Jing AnDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Jitong LouDepartment of Biostatistics, University of North Carolina, Chapel Hill, NC 27599, USA.
Qisheng GuUnit of Immunity and Pediatric Infectious Diseases, Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.
Weimin DingLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
Gaith DrobyDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Yilin WangDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Chenghao WangDepartment of Biostatistics, University of North Carolina, Chapel Hill, NC 27599, USA.
Yanzhe GaoDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Abigail SheltonDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Andrew Benson SatterleeEshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina, Chapel Hill, NC 27599.
Breanna Elizabeth MannEshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina, Chapel Hill, NC 27599.
Yun-Chung HsiaoDepartment of Environmental Sciences and Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Chih-Wei LiuDepartment of Environmental Sciences and Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Kun LiuDepartment of Environmental Sciences and Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Shawn HingtgenEshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina, Chapel Hill, NC 27599.
Jiguang WangDivision of Life Science, Department of Chemical and Biological Engineering, State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Hong Kong SAR, China.
Zhaoliang LiuInstitute of Cancer Prevention and Treatment, Heilongjiang Academy of Medical Sciences, Harbin Medical University, Harbin, China.
Ryan MillerDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Di WuDepartment of Biostatistics, University of North Carolina, Chapel Hill, NC 27599, USA.
Cyrus VaziriDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Yang YangDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
North Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3M
The UNC Chapel Hill Superfund Research Program (UNC-SRP)P42ES031007 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Rebecca Fry · 2020 to 2026
$22.2M
A Novel Carcinogen-Induced Cell Cycle CheckpointR01ES009558 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VAZIRI, CYRUS · 2002 to 2016
$4.8M
Defining Mechanisms of Pathological Trans-Lesion Synthesis During CarcinogenesisR01CA215347 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VAZIRI, CYRUS, WILLIAMS, SCOTT E · 2018 to 2022
$2.6M
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic targetR01CA229530 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEARCE, KENNETH HUGH, VAZIRI, CYRUS · 2019 to 2023
$2.0M
Andor Dragonfly 202 Spinning Disk Confocal Microscope for the University of North Carolina at Chapel HillS10OD030223 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARIEL, PABLO · 2021 to 2021
$474k
NCATS NIH HHS UL1 TR001111NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA215347NCI NIH HHS R01 CA229530NIEHS NIH HHS P30 ES010126NIEHS NIH HHS P42 ES031007NIEHS NIH HHS R01 ES009558NIH HHS S10 OD030223
6 · The paper itself

Abstract

Almost all Glioblastoma (GBM) are either intrinsically resistant to the chemotherapeutical drug temozolomide (TMZ) or acquire therapy-induced mutations that cause chemoresistance and recurrence. The genome maintenance mechanisms responsible for GBM chemoresistance and hypermutation are unknown. We show that the E3 ubiquitin ligase RAD18 (a proximal regulator of TLS) is activated in a Mismatch repair (MMR)-dependent manner in TMZ-treated GBM cells, promoting post-replicative gap-filling and survival. An unbiased CRISPR screen provides a new aerial map of RAD18-interacting DNA damage response (DDR) pathways deployed by GBM to tolerate TMZ genotoxicity. Analysis of mutation signatures from TMZ-treated GBM reveals a role for RAD18 in error-free bypass of O

Identifiers

PMID37905107
PMCPMC10614844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.